AROS Is a Significant Biomarker for Tumor Aggressiveness in Non-cirrhotic Hepatocellular Carcinoma.
Despite a low risk of liver failure and preserved liver function, non-cirrhotic hepatocellular carcinoma (HCC) has a poor prognosis. In the current study, we evaluated an active regulator of SIRT1 (AROS) as a prognostic biomarker in non-cirrhotic HCC. mRNA levels of AROS were measured in tumor and non-tumor tissues obtained from 283 non-cirrhotic HCC patients. AROS expression was exclusively up-regulated in recurrent tissues from the non-cirrhotic HCC patients (P = 0.015) and also in tumor tissues irrespective of tumor stage (P < 0.001) or BCLC stage (P < 0.001). High mRNA levels of AROS were statistically significantly associated with tumor stage (P < 0.001), BCLC stage (P = 0.007), alpha fetoprotein (AFP) level (P = 0.013), microvascular invasion (P = 0.001), tumor size (P = 0.036), and portal vein invasion (P = 0.005). Kaplan-Meir curve analysis demonstrated that HCC patients with higher AROS levels had shorter disease-free survival (DFS) in both the short-term (P < 0.001) and long-term (P = 0.005) compared to those with low AROS. Cox regression analysis demonstrated that AROS is a significant predictor for DFS along with large tumor size, tumor multiplicity, vascular invasion, and poor tumor differentiation, which are the known prognostic factors. In conclusion, AROS is a significant biomarker for tumor aggressiveness in non-cirrhotic hepatocellular carcinoma.
Cbs Bioscience Inc., Daejeon, Korea.
Jung-Hee
JH
Kwon
Department of Surgery, Keimyung University School of Medicine, Dongsan Medical Center, Daegu, Korea.
Keun Soo
KS
Ahn
Cbs Bioscience Inc., Daejeon, Korea.
Young Ho
YH
Moon
Cbs Bioscience Inc., Daejeon, Korea.
Jin Young
JY
Park
Department of Surgery, Ajou University School of Medicine, Suwon, Korea.
Hee Jung
HJ
Wang
Department of Life Science, Pohang University of Science and Technology, Pohang, Korea.
Kwan Yong
KY
Choi
Department of Microbiology, Pukyong National University, Busan, Korea.
Gundo
G
Kim
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jae Won
JW
Joh
Department of Surgery, Hanyang University School of Medicine, Seoul, Korea.
Kyeong Geun
KG
Lee
Department of Surgery, Keimyung University School of Medicine, Dongsan Medical Center, Daegu, Korea.
Koo Jeong
KJ
Kang
D000328:Adult; D017677:Age Distribution; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology* / Q000378:metabolism* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000453:epidemiology / Q000378:metabolism / Q000473:pathology; D008113:Liver Neoplasms / Q000453:epidemiology* / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009687:Nuclear Proteins / Q000378:metabolism*; D015995:Prevalence; D015203:Reproducibility of Results; D056910:Republic of Korea / Q000453:epidemiology; D012307:Risk Factors; D012680:Sensitivity and Specificity; D017678:Sex Distribution; D014157:Transcription Factors / Q000378:metabolism*; D055815:Young Adult
D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; C524448:RPS19BP1 protein, human; D014157:Transcription Factors
Biological Markers; Carcinoma, Hepatocellular; Prognosis